Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem, validační studie
PubMed
30561721
DOI
10.1093/ndt/gfy337
PII: 5250382
Knihovny.cz E-zdroje
- Klíčová slova
- IgA nephropathy, Oxford classification, immunosuppression, kidney biopsy, proteinuria,
- MeSH
- biopsie MeSH
- hodnoty glomerulární filtrace MeSH
- IgA nefropatie klasifikace farmakoterapie patologie MeSH
- imunosupresiva terapeutické užití MeSH
- lidé MeSH
- odchylka pozorovatele * MeSH
- prognóza MeSH
- reprodukovatelnost výsledků MeSH
- retrospektivní studie MeSH
- statistické modely * MeSH
- výběr pacientů * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- validační studie MeSH
- Názvy látek
- imunosupresiva MeSH
BACKGROUND: The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. RESULTS: All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). CONCLUSION: We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
Alessandro Manzoni Hospital Lecco Italy
Careggi University Hospital Florence Italy
German Cancer Research Center INF 280 Heidelberg Germany
Hacettepe University Institute of Children's Health Ankara Turkey
Hippokration General Hospital Aristotle University of Thessaloniki Thessaloniki Greece
Hôpital du Sacré Coeur de Montréal Montreal Canada
Hôpital Maisonneuve Rosemont Montreal Canada
Hospital Universitari de Bellvitge Barcelona Spain
Imperial College Hammersmith Hospital London UK
ISS Fundación Jiménez Díaz Madrid Spain
Istanbul University Istanbul Turkey
Karolinska Institute Stockholm Sweden
Leiden University Medical Center Leiden The Netherlands
Medical University of Silesia Katowice Poland
Medical University of Warsaw Warsaw Poland
National and Kapodistrian University of Athens Greece Athens Greece
Nephrology Department University Hospital October 12 Madrid Spain
Nephrology Fundacion Puigvert Barcelona Spain
Nephrology Medical School University of Ioannina Ioannina Greece
Nephropathology Radboud University Nijmegen Medical Center Nijmegen The Netherlands
Nephropathology San Gerardo Hospital Monza Italy
Oxford University Hospitals Oxford UK
Pathology Drug Safety and Metabolism IMED Biotech Unit AstraZeneca Gothenburg Sweden
Pathology G Brotzu Hospital Cagliari Italy
Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic
Pathology Leicester General Hospital Leicester UK
Pathology Policlinic of Modena and Reggio Emilia Modena Italy
Pathology S Andrea Hospital Rome Italy
Pathology S Croce Hospital Cuneo Italy
Pathology Tartu University Clinics Tartu Estonia
Pathology University of Turin Italy
Pathology Western Infirmary Glasgow Glasgow UK
Sapienza University of Rome Rome Italy
School of Medicine University Hospital Dubrava University of Zagreb Zagreb Croatia
Spedali Civili di Brescia Brescia Italy
Toronto General Hospital University Health Network Toronto Ontario Canada
Transplantation Medicine and Nephrology Warsaw Medical University Warsaw Poland
Citace poskytuje Crossref.org